Myagmarsuren, Erdenetuya
Loading...
Товч нэр
Myagmarsuren, Erdenetuya
Бүтэн нэр
Myagmarsuren Erdenetuya
Латин нэр
Myagmarsuren Erdenetuya
Албан тушаал
Судлаач
ORCID
5 results
Now showing 1 - 5 of 5
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Management of Cardiovascular Medicines Used at the Regional Diagnostic and Treatment Center of the Western Region of Mongolia(2021-04-13) ;Dulmaa Lkhagvasuren; ; As cardiovascular diseases are the major global health problem, the management of cardiovascular medicines (CVMs) should not be out of attention. We aimed to identify CVMs needing strict management control, used in 2017 and 2018 to investigate if there was a possibility to make savings in the expenditure for CVMs if the proper management was done regarding Class A medicines at the Regional Diagnostic Treatment Center of Khovd aimag in 2018. Aggregate data methods, Always, Better and Control (ABC), Vital, Essential and Non-essential (VEN), and ABC-VEN matrix analyses were used to identify the categories of CVMs, included in the Essential Medicine List of Mongolia for the year 2017 and 2018. Class A medicines represented 23.81% and 30.43% of the total CVMs and consumed the largest proportion of the total budgets at 73% and 71% in 2017 and 2018, respectively. The Category I, which requires strict management control, contains the majority (an average of 59%) of total CVMs and amounting for an average of 78.67% of total expenditures in 2017 and 2018. We conclude that the Regional Diagnostic and Treatment Center could have saved a total of 6,646,500 MNT if the proper management regarding Class A medicines was done in 2018 based on the results of ABC, VEN, and ABC-VEN matrix analyses of 2017. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Biochemical and Hematological Patterns of Hospitalized COVID-19 Patients in Mongolia(Mongolian National University of Medical Sciences, 2023-11-06); ; ; Objectives: The impact of COVID-19 prompted a race to find a treatment that would reduce its mortality. This study aimed to analyze how the clinical and laboratory characteristics reflect the disease process and progression of COVID-19 cases in hospitalized patients of Mongolia, which could be informative in managing patients with COVID-19. Methods: A cross-sectional study was conducted on the prescription patterns of drugs given to hospitalized patients diagnosed with COVID-19. A total of 1012 participants were recruited in the study. These were identified from the reported positive cases by polymerase chain reaction or antigen reactivity performed in Ulaanbaatar. Result: A total of 1096 patients participated in this study. The mean age was 51.86 ± 16.98 for male patients and 52.23 ± 16.4 for female patients. It has been revealed that there are statistically significant differences between male and female patients. RBC was 4.56 ± 0.79 M/ UL and 5.08 ± 1.36 M/UL, men and women respectively. The levels of C-reactive protein (CRP) in female COVID-19 patients were significantly higher (46.75 ± 72.83 mg/dL) compared to male patients (33.94 ± 47.96 mg/dL). The platelet count (PLT) was 245.32 ± 77.71 for male patients, while there was a significant reduction in PLT count in female patients (229.30 ± 71.59). Conclusions: Patients with COVID-19 in Mongolia appeared to remain in the hospital for 6.86 ± 2.43 days, shorter than in other countries. Hematological analysis showed that female patients had elevated C-reactive protein levels and decreased PLT count. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A Randomized Trial of Vitamin D Supplementation and COVID-19 Clinical Outcomes and Long COVID: The Vitamin D for COVID-19 Trial(2026-04); ;Cook, Kaitlyn A ;Khudyakov, Polyna; BACKGROUND: Data from randomized controlled trials of vitamin D3 supplementation in modifying the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are sparse. OBJECTIVES: We evaluated the effect of vitamin D3 supplementation on healthcare utilization and other clinical outcomes among adults with coronavirus disease 2019 (COVID-19) and their close contacts. METHODS: We conducted a parallel 2-group randomized controlled double-blinded trial targeting free-living adults in the United States and Mongolia. Index participants with newly diagnosed COVID-19 were cluster-randomized with up to one of their cohabiting contacts either to an oral vitamin D3 loading dose of 9600 IU/d for 2 d followed by 3200 IU/d for 4 wk or to placebo. Participants completed weekly questionnaires on healthcare utilization, disease severity, and long COVID (index participants) or new SARS-CoV-2 infection (household contacts). The primary outcome was ≥1 healthcare visits (including hospitalization) or death within 4 wk among the index participants. RESULTS: Index participants (n = 1747) were a median of 38.0 y old (IQR: 31.1-47.0), 65.6% female/other sex, 4.2% Black non-Hispanic, 4.8% Hispanic/Latinx, 43.2% Asian, 44.3% non-Hispanic White, and 44.9% vitamin D deficient or insufficient (25-hydroxyvitamin D3 <20 ng/mL). Baseline characteristics for the household contacts (n = 277) were similar. The 4-wk cumulative incidence of healthcare utilization in index participants did not significantly differ between the vitamin D3 (n = 863) and placebo (n = 884) groups [cumulative incidences, 0.28 compared with 0.29; odds ratio (OR), 0.97; 95% confidence interval (CI): 0.75, 1.24]. Similar nonsignificant results were observed for the prespecified secondary treatment and prevention outcomes, though per-protocol analyses showed a nonsignificant trend toward benefit of vitamin D3 on the prevalence of long COVID at 8 wk (OR, 0.78; 95% CI: 0.59, 1.03). No safety concerns were identified. CONCLUSIONS: Among adults with newly diagnosed SARS-CoV-2 infections, vitamin D3 supplementation did not significantly change the 4-wk cumulative incidence of healthcare utilization or COVID-19-related outcomes compared with placebo. Promising results for long COVID warrant further study. This study was registered at clinicaltrials.gov as NCT04536298. First registered on 1 September, 2020.Scopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we?(2021-03) ;Zulzaga, Zuzaan; ;Woerdenbag, Herman Jvan Puijenbroek, Eugene P - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Antibiotic and antiviral prescribing patterns among hospitalised patients with COVID-19 pneumonia in Mongolia: a real-world descriptive retrospective studyBACKGROUND: During the COVID-19 pandemic, Mongolia, like many low- and middle-income countries, faced major healthcare delivery challenges due to limited system readiness, resource constraints, geopolitical vulnerabilities, and prolonged border closures. These factors caused shortages of laboratory reagents and globally recommended therapeutics, including remdesivir and tocilizumab, prompting clinicians to use alternative antivirals and empirical broad-spectrum antibiotics. OBJECTIVE: To evaluate and compare real-world prescribing patterns of antibiotics and antivirals among hospitalised patients with COVID-19 pneumonia at Mongolia's two largest tertiary referral facilities: Mongolia-Japan Hospital (MJH) and the National Center for Communicable Diseases (NCCD). METHODS: This retrospective cross-sectional study analysed anonymised medical charts and electronic health records of 1012 adults with PCR-confirmed COVID-19 pneumonia hospitalised between 18 April and 31 December 2021. Demographics, comorbidities, laboratory markers, and pharmacological treatments were systematically extracted and compared between the two institutions. RESULTS: Antibiotics were prescribed to 87.6% (887/1012) of patients. Cephalosporins were the most frequently prescribed class (89.3%, 904/1012), followed by macrolides (36.5%, 369/1012) and fluoroquinolones (33.5%, 339/1012). Multi-drug empiricism was common, with beta-lactam, macrolide, and quinolone combinations accounting for 70.8% (68/96) of triple-antibiotic regimens. Antivirals were administered to over 90% of patients, predominantly umifenovir (52.2%) and favipiravir, supported by domestic stockpiles and Eurasian trade networks. Remdesivir was rarely used, while tocilizumab was administered to only 2 patients (0.2%). Hypertension and diabetes were significantly more frequent in the MJH cohort, reflecting differences in catchment populations and screening practices. CONCLUSION: The high rate of empirical broad-spectrum antibiotic use and reliance on alternative antivirals reflect pragmatic clinical adaptations to diagnostic reagent shortages and therapeutic supply inequities. These findings highlight the need for national antimicrobial stewardship programmes, strengthened microbiological diagnostic capacity, and digitised clinical registries to improve healthcare system resilience in resource-constrained settings.
